Shares of Astrazeneca PLC (AZN) Rally 0.43%

On a relative basis, the stock has outperformed the S&P 500 by 5.05% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.43% in the last 1 week, and is up 9.64% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.08% and the 50-Day Moving Average is 4.07%.

Astrazeneca PLC (NYSE:AZN): The stock opened at $30.42 on Friday but the bulls could not build on the opening and the stock topped out at $30.46 for the day. The stock traded down to $30.12 during the day, due to lack of any buying support eventually closed down at $30.24 with a loss of -0.33% for the day. The stock had closed at $30.34 on the previous day. The total traded volume was 7,349,686 shares.


Institutional Investors own 10.18% of Astrazeneca PLC shares.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.